The tweet was deleted by the author.
But we saved everything 🙂.
Upstream Bio, Inc. will present additional analyses from the Phase 2 VIBRANT trial of its drug verekitug for chronic rhinosinusitis with nasal polyps (CRSwNP) at the EAACI2026 congress in Istanbul.
The presentation, scheduled for Sunday, June 14, will feature a responder analysis focusing on key measures of disease. Industry observers will closely watch for new clinical insights as the company shares results in Room Munich.
Upstream Bio previously released initial Phase 2 VIBRANT trial data on verekitug for CRSwNP with comorbid asthma at the ATS2026 conference. The company is also set to attend the Goldman Sachs Global Healthcare Conference in Miami, where it will host a fireside chat on June 10. These events underline the company's ongoing efforts to engage both clinical and investment communities.